Amgen To Participate At Citi's 8th Annual Biotech Conference

         Amgen To Participate At Citi's 8th Annual Biotech Conference

PR Newswire

THOUSAND OAKS, Calif., Aug. 30, 2013

THOUSAND OAKS, Calif., Aug. 30, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will
participate at Citi's 8^th Annual Biotech Conference on Tuesday, Sept. 3,
2013, in Boston, beginning at 2:00 p.m. Eastern Daylight Time. Scott Foraker,
vice president and general manager of Biosimilars at Amgen, will participate
in a panel at the conference entitled "Biosimilars: Risks & Opportunities –
Looking at the Crystal Ball." Live audio of the presentation can be accessed
from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A
replay of the webcast will also be available on Amgen's website for 90 days
following the event.

About Amgen
Amgen is committed to unlocking the potential of biology for patients
suffering from serious illnesses by discovering, developing, manufacturing and
delivering innovative human therapeutics. This approach begins by using tools
like advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics
manufacturing expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer since 1980,
Amgen has grown to be the world's largest independent biotechnology company,
has reached millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

SOURCE Amgen

Website: http://www.amgen.com